NeoStem, Inc. in-licensed worldwide rights to Primcel, a mesenchymal (bone marrow) stem cell product that, in early clinical studies, shows promise of accelerating the healing of chronic wounds. NeoStem has opened adult stem cell collection sites in the US and has invested in regenerative medicine companies in China. When NeoStem received new capital from Asian investors in April 2009, the company declared its intention to enter the medical tourism business. More details...

Stock Symbol: (NYSE Amex: NBS)